Correlation Between Intra-abdominal Pressure, Biomarkers of Bacterial Translocation and Intestinal Wall Damage

NCT06221293 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-04-19

No results posted yet for this study

Summary

Main scientific hypotheses of the project:

1\. The level of intestinal microflora translocation markers and biomarkers of intestinal wall damage the in the blood serum correlates with the level of intra-abdominal pressure, regardless of the genesis of intra-abdominal hypertension.

2\. The critical levels of intestinal microflora translocation markers and biomarkers of the intestinal wall damage can be used for predicting an unfavorable outcome in the multiple organ dysfunction syndrome.

3\. The revealed critical level of intra-abdominal pressure is an additional prognostic sign in assessing the course of the multiple organ dysfunction syndrome.

. Project objectives:

1. To evaluate the indicators of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage in the systemic circulation during the development and course of the syndrome of multiple organ dysfunction. Based on the obtained critical levels of markers of translocation of the intestinal microflora and markers of the intestinal wall damage, it will be possible to predict adverse outcomes in patients with multiple organ dysfunction syndrome.
2. To identify differences in the level of markers of bacterial translocation of the intestinal microflora and the level of markers of the intestinal wall damage in patients with intra-abdominal hypertension. In patients with multiple organ dysfunction syndrome, the levels of biomarkers of bacterial translocation of the intestinal microflora and biomarkers of intestinal wall damage in the blood serum correlate with intra-abdominal pressure indicators, regardless of the etiology of intra-abdominal hypertension.
3. Assess the impact of the level of intra-abdominal pressure on the development and course of the syndrome of multiple organ dysfunction. To assess the course of the syndrome of multiple organ dysfunction, an additional prognostic marker is the determination of the critical level of intra-abdominal pressure.
4. Determine the critical levels of biomarkers of intestinal microflora translocation and biomarkers of intestinal wall damage to predict the outcome of diseases accompanied by the development of multiple organ dysfunction syndrome. The obtained critical levels of biomarkers of translocation of the intestinal microflora and biomarkers of the intestinal wall damage will be significant indicators in the syndrome of multiple organ dysfunction for predicting an unfavorable outcome.

Conditions

  • Intraabdominal Hypertension
  • Multi-Organ Disorder
  • Translocation Syndrome

Interventions

DIAGNOSTIC_TEST

immunoenzyme analysis

immunoenzyme analysis with EVOLIS system

Sponsors & Collaborators

  • Karaganda Medical University

    lead OTHER

Principal Investigators

  • Alina Ogizbaeva, dr · young scientist, phD

  • Kairat Shakeyev, dr · head of the surgical service of the CSE "Multidisciplinary Hospital No. 3 of Karaganda

  • Dmitry Matyushko, dr · PhD, Associate Professor of the Department of Surgical Diseases

  • Miras Mugazov, dr · PhD, Associate Professor of the Department of Emergency Medical Care

  • Dana Amanova, dr · PhD, young scientist, co-investigator

  • Zhibek Zhumadilova · young scientist, co-investigator

  • Shynggys Nuraly · young scientist, co-investigator

  • Sofiko Assamidanova · young scientist, co-investigator

  • Yermek Turgunov, dr · professor

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2025-12-25
Completion
2025-12-27

Countries

  • Kazakhstan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06221293 on ClinicalTrials.gov